Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TGA wants to raise age for OTC cough/cold products

This article was originally published in The Tan Sheet

Executive Summary

The Australian Therapeutic Goods Administration recommends raising the minimum age for OTC pediatric cough and cold products to 6 years - the same age 1U.K. regulators recommend and two years older than in the 2U.S. TGA bases the recommendation on an external safety review of data summarized in Australia's 3review of cough and cold medicines in children. It also wants the 4National Drugs and Poisons Schedule Committee to make cough and cold products for 6- to 12-year-olds available only from a pharmacist, and wants manufacturers to package all cough and cold products in child-resistant containers by July 2010

You may also be interested in...

U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation

Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use

Standardize Wording, Dosing Devices of Pediatric Cold Products – NDAC

FDA advisory committees recommend not only standardizing language on OTC pediatric cough/cold product labels, but also dosing devices for the products

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts